Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response

Measurable residual disease (MRD) testing after initial chemotherapy treatment can predict relapse and survival in acute myeloid leukemia (AML). However, it has not been established if repeat molecular or genetic testing during chemotherapy can offer information regarding the chemotherapy sensitivit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Hong Yuen, Sung, Anthony D., Lindblad, Katherine E., Sheela, Sheenu, Roloff, Gregory W., Rizzieri, David, Goswami, Meghali, Mulé, Matthew P., Ramos, Nestor R., Tang, Jingrong, Thompson, Julie, DeStefano, Christin B., Romero, Kristi, Dillon, Laura W., Kim, Dong-Yun, Lai, Catherine, Hourigan, Christopher S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341003/
https://www.ncbi.nlm.nih.gov/pubmed/30697529
http://dx.doi.org/10.3389/fonc.2018.00669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341003/
https://www.ncbi.nlm.nih.gov/pubmed/30697529
http://dx.doi.org/10.3389/fonc.2018.00669

Ejemplares similares